Introduction
Protein prenylation is a post-translational lipid modification characterized by the presence of either a farnesyl group (C15) or a geranylgeranyl group (C20) near the C terminus of a protein. Prenylated proteins comprise at least 1 % of the proteome, are involved in almost all signal transduction pathways, and are over-expressed in 50 % of all human tumors. [1] These proteins are either geranylgeranylated or farnesylated depending on the terminal amino acid (X) in the tetrapeptide "CAAX box" sequence that is found at the C terminus of all prenylated proteins. In this sequence C is a cysteine, A is an aliphatic amino acid and X is any amino acid. Farnesylated proteins are prenylated by PFTase (protein farnesyl transferase) while geranylgeranylated proteins are prenylated by PGGTase (geranylgeranyl transferase). Commonly "CAAX box" proteins that end in either A or M are farnesylated and proteins that end in L are geranylgeranylated. [2] "CAAX" box proteins that end in S can be either geranylgeranylated or farnesylated. Recombinant yeast [3] and mammalian [4] forms of each of these enzymes have been expressed in E. coli and have been used to prenylate both proteins and peptides in ex vivo experiments.
Many studies have been performed on the substrate fidelity of both PGGTase and PFTase. These studies showed that both enzymes can transfer nonnatural FPP and GGPP analogues onto "CAAX box" containing substrates. These prenyl diphosphate analogues have been designed to include fluorescent [5] or photoaffinity [6, 7] labels as well as bioorthogonal tags, such as alkynes [8, 9] and azides. [10] [11] [12] [13] [14] Such prenyl analogues have been transferred to CAAX-containing peptides, naturally prenylated proteins, or proteins that have had "CAAX box" sequences appended to their C terminus through site-directed mutagenesis. For instance, Duckworth et al. have tagged GFP containing a C-terminal "CAAX" box with alkyne and azide FPP analogues 1 [9] and 2 [13] (Scheme 1). These analogues were then used to create protein-protein, protein-DNA, and proteinagarose conjugates by using Cu(I)-catalyzed click reactions with alkyne-labeled proteins, DNA, and agarose.
The aforementioned prenyl analogues are all constructed from geranyl, farnesyl, or geranylgeranyl moieties containing two, three, or four isoprenoid units. In this work, we report the transfer of a non-natural prenyl analogue based on a single isoprenoid unit, 3-methyl-2-buten-1-ol, to "CAAX box" proteins and a "CAAX box" peptide using PFTase. This prenyl diphosphate (3) is the least bulky alkyne or azide labeled prenyl substrate reported for PFTase to date and thus makes 3 the least intrusive and least hydrophobic modification available for labeling of "CAAX box" containing biomolecules. This is important because modifying molecules with longer hydrophobic chains significantly decreases their solubility. To further extend this minimization approach of modifying biomolecules by using the prenyl transfer method, the last three amino acids of the "CAAX box" of a peptide and a protein labeled with alkyne 3 were removed enzymatically. This allows for alkyne labeling of "CAAX box" containing molecules with the net gain of a Recently a number of nonnatural prenyl groups containing alkynes and azides have been developed as handles to perform click chemistry on proteins and peptides ending in the sequence "CAAX", where C is a cysteine that becomes alkylated, A is an aliphatic amino acid and X is any amino acid. When such molecules are modified, a tag containing a prenyl analogue and the "CAAX box" sequence remains. Here we report the synthesis of an alkyne-containing substrate comprised of only nine nonhydrogen atoms. This substrate was synthesized in six steps from 3-methylbut-2-en-1-ol and has been enzymatically incorporated into both proteins and peptides by using protein farnesyltransferase. After prenylation the final three amino acids required for enzymatic recognition can be removed by using carboxypeptidase Y, leaving a single residue (the cysteine from the "CAAX box") and the prenyl analogue as the only modifications. We also demonstrate that this small tag minimizes the impact of the modification on the solubility of the targeted protein. Hence, this new approach should be useful for applications in which the presence of a large tag hinders the modified protein's solubility, reactivity, or utility.
single cysteine residue attached to a prenyl analogue containing only nine nonhydrogen atoms.
Results and Discussion
Previously geranyl diphosphate (GPP) has been shown to be a substrate for PFTase even though it is one isoprenoid unit shorter than the enzyme's natural substrate, FPP. [15] The study reported here concentrates on compound 3, which is based on dimethylallyl diphosphate (consisting of a single isoprenoid unit) in order to prenylate "CAAX box" containing proteins or peptides. Using 3 as a substrate allows for the selective addition of a clickable alkyne moiety without the addition of a large, hydrophobic isoprenoid.
Synthesis of alkyne diphosphate (3)
The synthesis of alkyne-containing prenyl diphosphate analogue 3 was completed in six steps from 3-methylbut-2-en-1-o1 (Scheme 2) in a 7.9 % overall yield. Dimethylallyl alcohol was protected with dihydropyran, and oxidized to give alcohol 6. [6, 16] The resulting alcohol was converted into alkyne 7 through Williamson ether synthesis by alcohol deprotonation with NaH and subsequent addition of propargyl bromide. Deprotection of 7 with PPTs gave alcohol 8, which was converted to alkyl bromide 9 by treatment with CBr 4 and polymer-supported PPh 3 . Bromide 9 was converted to diphosphate 3 by treatment with [(nBu) 4 N] 3 HP 2 O 7 [17] and purified by using ion-exchange chromatography and RP-HPLC. For subsequent use, compound 3 was dissolved in 25 mm NaHCO 3 and its concentration was subsequently quantified by using 31 P NMR spectroscopy with an internal standard of phosphoric acid. The final product and all intermediates were characterized by 1 H NMR, 13 C NMR, and ESI-MS.
Evaluation of 3 as a substrate for PFTase by using a peptide model Diphosphate 3 was first investigated as a potential PFTase substrate by using a fluorescent HPLC based assay. A "CAAX box" containing peptide, OrG-RTRCVIA-OH (12), was prepared by synthesizing the linear peptide sequence by SPPS and coupling the fluorophore (10) to the N terminus by using DIPCDI, HOBt and DIEA in DMF. Initial attempts to analyze 3, as well as other longer nonnatural isoprenoid diphosphates as substrates for PFTase were carried out by using dansylated peptides, such as N-dansyl-GCVIA; however, the prenylated products of these reactions were not sufficiently soluble in aqueous media. Thus, we abandoned efforts with the dansylated peptides in favor of Oregon Green-conjugated peptide 12, which was substantially more water soluble due to the presence of multiple charged arginine resides upstream of the required CVIA prenylation recognition sequence. In addition, the Oregon Green fluorophore has a much higher quantum yield than the dansyl fluorophore and in turn requires lower peptide concentrations for analysis. In order to determine whether prenyl analogue 3 was a substrate for PFTase, it was incubated with the enzyme and peptide 12 at 30 8C in the presence of Zn 2 + and Mg 2 + . At various time intervals, aliquots were removed and analyzed by HPLC to monitor the conversion from 12 to 13. Nearly complete conversion (> 85 %) was observed after incubating peptide 12 with an excess of 3 for 24 h by using typical prenylation conditions. Prenylated product 13 was isolated by HPLC, and its identity was confirmed by using LC-MS. 
Kinetic analysis of 3 using a peptide substrate
While the above experiments established that alkyne 3 was a substrate for PFTase, it was desirable to determine the efficiency of incorporation of 3 compared to the natural substrate, FPP. In previous studies, we have typically employed a continuous spectrofluorometric assay to measure the rate of enzymatic incorporation. That assay monitors the time-dependant increase in the fluorescence of a dansylated peptide as it becomes farnesylated; the increase in hydrophobicity due to prenylation results in an increase in the fluorescence intensity of the proximal dansyl group. Unfortunately, the smaller size of 3 decreases the magnitude of this effect; the calculated log P for farnesol is 5.0 compared to 0.3 for alcohol 8. Thus, no significant change in dansyl group fluorescence was observed when the peptide N-dansyl-GCVIA was incubated with 3 in the presence of PFTase. To circumvent this problem, an HPLC assay based on the separation between peptide substrate 12 and its prenylated congener 13 was employed (by using the separation shown in Figure 1 ). After establishing the conditions in which the initial rate was linear, reactions containing 12, 3 (or FPP) and PFTase were performed, fractionated by HPLC and the amount of product formed was calculated by integration of the chromatograms. The apparent K M,app and V max,app parameters were determined for each isoprenoid substrate from direct plots of the rate versus substrate concentration (reported as K M,app and V max,app since the analysis for this bisubstrate reaction was performed at only a single peptide substrate concentration). That analysis gave K M,app values of 2.3 and 180 mm for FPP and 3, respectively; this suggests that 3 binds to PFTase with substantially less affinity (78-fold lower) than FPP. The above kinetic analysis also yielded a value for V max,app for 3 that was 400-fold lower than that for FPP. This was somewhat surprising since the V max value for geranyl diphosphate, an isoprenoid of comparable size to 3, is similar to that for FPP. Clearly, subtle modifications in the structure beyond the first isoprene unit can still influence the efficiency of incorporation of an isoprenoid substrate. Despite the lower efficiency of incorporation of 3 by PFTase, the ease of synthesis of 3 compared with analogues based on larger isoprenoids coupled with the ready access to significant amounts of PFTase make experiments with this minimized substrate an attractive alternative to larger, more hydrophobic and complex substrates.
Proteolytic removal of "AAX" residues by carboxypeptidase treatment After establishing that 3 was a PFTase substrate, we next sought to pursue a minimization strategy that would remove the C-terminal tripeptide (VIA) from the "CAAX box" by proteolysis. If those residues required for PFTase recognition could be removed after prenylation, modification of biomolecules by using this method is accomplished with only the net gain of a single cysteine with a modified side chain. Since the "CAAX box" is found at the C terminus of PFTase substrates, carboxypeptidase Y (CPY) was used to cleave off the "AAX" residues. Previous studies have shown that carboxypeptidase stalls at farnesylated and geranylgeranylated cysteine. [18] [19] [20] Hence, we predicted that prenylation with 3 followed by proteolysis would result in removal of only the three C-terminal amino acids, "AAX", that followed the modified cysteine. However, the effect of smaller isoprenylated cysteine residues on carboxypeptidase stalling had not been previously evaluated. Given this uncertainty, we elected to study this question using prenylated peptides prior to proceeding with larger protein substrates, the characterization of which is more difficult.
Accordingly, purified prenylated peptide 13 was converted to its proteolyzed homologue 14 directly or was converted to 14 in one pot by addition of CPY and EDTA after most of 12 was converted to 13 by PFTase. Using LC-MS, the CPY cleavage reaction was observed to be complete within minutes after addition of CPY (used at low micromolar concentrations). Completion was indicated by the absence of any starting material as observed by MS and HPLC. CPY-cleaved samples of 13 were also analyzed for cleavage fragments upstream of the modified cysteine side chain. None of the masses for products proteolyzed beyond the modified cysteine was observed. This provides good evidence that CPY cannot cleave through the modified cysteine residue due to its excessive size. Hence, since CPY does not cleave past the modified cysteine, "CAAX box" containing proteins should also have their final three amino acids safely cleaved by using this method.
Prenylation and proteolysis of mCherry
Modifying amino acid residues in proteins is commonly done by treating Cys or Lys residues with activated succinimidyl esters or maleimides, respectively. These protein-modification methods while robust, lack the ability to specifically label individual Cys or Lys residues. A plethora of enzymes exist that are responsible for the post-translational modification of proteins. [21] These enzymes require amino acid recognition se- Chromatogram (2): prenyl alkyne modified OrG-RTRCVIA (13; t R = 41 min).
Chromatogram (3): prenylated peptide 14 (t R = 36 min) that has had the last three amino acids of its "CAAX box" removed by the enzyme CPY. Fluorescence intensity is reported in relative fluorescence units (RFU).
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www.chembiochem.org quences of varying lengths to guide them to the specific amino acid targeted for modification. In the case of PFTase, the required recognition sequence is only four amino acids long. [22, 23] The brevity of this sequence along with the promiscuity of PFTase provides a unique opportunity to use this enzymatic process for the site-specific labeling of proteins at cysteine resides near the C terminus of proteins. This labeling technique can also be used on nonnaturally prenylated proteins by appending a CVIA tag at the protein's C terminus by site-directed mutagenesis and subsequently over-expressing the modified protein in E. coli. Using this method, virtually any protein can be functionalized with a versatile alkyne moiety.
Having validated the incorporation of 3 into peptides using PFTase, we next sought to apply this to a protein that was not naturally prenylated. PCR-based insertion was used to append a CVIA peptide tag to the C terminus of mCherry to render the fluorescent protein a PFTase substrate. [24] mCherry was used due to its fluorescent properties and relative stability. Previously CVIA-modified mCherry has been prenylated with FPP as well as with nonnatural, bioorthogonal prenyl substrates. [24] In this previous work, mCherry was prenylated with an azidefunctionalized farnesyl analogue and subsequently attached to alkyne-functionalized agarose by using Cu I -catalyzed, [3+2] Huisgen cycloaddition. In the present work, mCherry-CVIA was prenylated with alkyne-functionalized 3 by PFTase to yield prenylated protein 16. The use of isoprenoid diphosphate 3 for this enzymatic transfer is particularly notable since it is the smallest alkyne isoprenoid substrate known for PFTase.
In order to demonstrate the modification of mCherry by 3, the putatively modified product 16 was subsequently treated with azide-functionalized agarose by using Cu I -catalyzed, Huisgen cycloaddition. After treatment for 2 h, the supernatant was removed and the beads were exhaustively washed to remove any noncovalently bound proteins. Fluorescence microscopy revealed that the beads treated with mCherry modified with 3 (16) in the presence of copper, TBTA ligand, and TCEP turned bright red (Figure 2 A) due to the conjugation of the red fluorescent protein by a triazole linkage to the agarose beads. Control experiments in which the beads were incubated in the presence of 16 but in absence of copper (Figure 2 B) or unprenylated mCherry (Figure 2 C) showed no significant fluorescence signal. Thus, these results support the conclusion that mCherry can be modified by PFTase by using 3 as a substrate and successfully immobilized.
Reactivity of "VIA" deficient mCherry protein Prenylated mCherry protein 16 was treated with CPY under conditions that were shown to completely remove the final three amino acids of peptide 13. After treatment, the protein was concentrated and linked to agarose beads as described above. The fluorescence intensity of beads linked with "VIA" deficient protein 17 (20) was similar to that of beads treated with full-length mCherry protein 16 (19) when analyzed by using the same imaging conditions (Figure 3 ). This indicates that the CPY treatment did not proteolyze past the prenylated cysteine within the "CAAX box". If CPY had read though the modified cysteine, then the resulting protein would not have had an alkyne available for cycloaddition to the azide-modified agarose. Also, since the fluorescence intensity of the beads closely matched that of the beads clicked to mCherry protein 16 under the same conditions, the data suggest that the fulllength and proteolyzed forms of prenylated mCherry (16 and 17, respectively) are immobilized with comparable efficiencies; it should be noted that CPY treatment had no deleterious effect on the reactivity or stability of the alkyne-modified protein. Compromised solubility in aqueous solutions is a potential problem when modifying proteins with hydrophobic lipid moieties. One motivation for our current study was to define a minimal alkyne-containing PFTase substrate that could circumvent this issue. We chose the homohexameric ring-shaped protein, Hcp1, from Pseudomonas aeruginosa as a model for comparing the relative impact of modification with 3 versus larger, previous generation lipid substrates. Hcp1 was chosen for these studies because the C terminus of the protein readily tolerates fusions, is solvent accessible, and faces the exterior ring surface. [25] Furthermore, the feasibility of in vitro isoprenoid modification of oligomeric proteins had not yet been ascertained.
We designed and generated an expression construct for Hcp1 containing a C-terminal His 6 -tag followed by the "CAAXbox" sequence "CVIA" (Hcp1-CVIA). This protein was expressed, purified, and modified with 3 or with the larger C15-dihydroazide compound (2) in a similar manner described above. Trypsin digestion and subsequent MS analysis of the prenylated samples showed efficient incorporation of the isoprenoid compounds. The predicted C-terminal peptides containing the isoprenoid modification (3, m/z 2132.0; 2, m/z 2257.2) were readily detected, however, the corresponding unmodified peptide (m/z 2010.0) was only detected in a control sample containing unreacted Hcp1-CVIA (Figure 4 A) . Thus, our MS analysis suggests that Hcp1 is nearly quantitatively modified with both substrates under these conditions. Interestingly, our results also indicate that nearly complete derivatization of multimeric proteins can be accomplished.
Next, we evaluated the solubility of Hcp1 modified with 2 or 3. Semiquantitative Western blot analysis was used to compare the concentration of protein present in the whole reaction to that which remained in the soluble fraction following highspeed centrifugation. As shown in Figure 4 B, soluble C15-modified Hcp1-CVIA (24) was not detected, whereas soluble C5-modified Hcp1-CVIA (22) was present at a level equivalent to that found in the whole reaction. Thus, the solubility properties of Hcp1-CVIA can be dramatically affected by the nature of the isoprenoid employed for modification.
CPY proteolysis of alkyne-modified Hcp1
Hcp1 that was prenylated with 3 (22) was subsequently treated with CPY in order to remove the last three C-terminal amino acids, VIA, that are required for enzymatic prenylation. In a one-pot reaction, CPY was added to Hcp1 that was previously incubated with PFTase, 3, Zn 2 + , and Mg 2 + for 2 h. The protein in the reaction mixture was subsequently trypsinized and analyzed by mass spectrometry. The predicted C-terminal peptide containing isoprenoid modification and the loss of the last three amino acids was detected (m/z 1848.9; Figure 4 C); however, the prenylated Hcp1 fragment with an intact "CAAX box" was not found (m/z 2132.0). Thus, prenylation and CPY proteolysis of Hcp1 resulted in the net attachment of a prenylated cysteine residue to the C terminus of the protein. In the end, this allows for the addition of alkyne functionality to a protein in a manner that limits the "tag" present in the final product to a single Cys at the protein's C terminus.
Conclusions
Modifying "CAAX box" containing proteins with nonnatural prenyl diphosphates is an efficient way to append useful functionality near the C terminus of a polypeptide. Even if a protein does not naturally end in a "CAAX" sequence it can be changed to include the sequence by simple genetic manipulation. Using this method allows virtually any protein to be modified near its C terminus with bioorthogonal functionality. One potential limitation of this method results from the increase of a protein's hydrophobicity (and hence solubility) after prenyl modification. Using shorter, nonnatural prenyl substrates, such as compound 3 to modify proteins curtails the increase of hydrophobicity that stems from prenyl modification. Furthermore, the final three amino acids of the "CAAX box" that are required for prenylation of proteins and peptides can also be enzymatically removed by treatment with carboxypeptidase Y. The peptidase removes the final three amino acids, but does not efficiently read through a prenylated cysteine. Removing these three nonpolar amino acids further reduces the net amount of hydrophobicity needed to be added to modify proteins with this method. In summary, by using this approach proteins and peptides can be specifically modified with alkyne functionality with a net gain of a single added cysteine the side chain of which is modified with only nine additional nonhydrogen atoms. This should be useful for a variety of applications in protein chemistry.
Experimental Section
General: All synthesis reactions were carried out at room temperature unless otherwise noted. Thin layer chromatography was done by using aluminum plates precoated with silica gel 60 from EMD chemicals. Plates were stained by using KMnO 4 since all synthesized compounds contained unsaturated functionality. Flash chromatography silica gel (60-200 mesh, 75-250 mm) was obtained from Mallinckrodt, Inc.
1 H NMR spectra were obtained at 200 or 300 MHz. 13 C NMR were obtained at 125 or 75 MHz.
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P NMR spectra were obtained at 242 MHz. All spectra were obtained on Varian instruments at 25 8C. HPLC separations were performed by using a Beckman 166 instrument, equipped with a UV detector, a fluorescence detector (Chromtech) and a Phenomenex C 18 column (Luna, 10 mm, 10 250 mm) attached to a 5 cm guard column for preparative separations and a Varian C 18 column (Microsorb-MV, 5 mm, 4.6 250 mm) for analytical separations. All UV traces were collected at 214 nm and all fluorescence data were collected by using l ex = 492 nm and l em = 520 nm. Preparative separations were accomplished by using a flow rate of 5 mL min À1 while analytical runs were carried out by using a flow rate of 1 mL min
À1
. Unless otherwise noted solvent A was 0.1 % TFA in H 2 O and solvent B was 0.1 % TFA in CH 3 CN. HR-ESI-MS was done by using a Bruker Bio TOF II instrument. MALDI-TOF was completed by using a 4800 MALDI-TOF/ TOF mass analyzer from Applied Biosystems, Inc. Recombinant yeast PFTase was over-expressed in E. coli BL21(DE3)/pRD577 cells, harvested in 1 L cultures, and purified by using ion exchange and 2938 www.chembiochem.org affinity chromatography to yield enzyme with a specific activity of 0.22 mmol·min À1 mg
. [3] Purified enzyme was stored in 20-100 mL aliquots in glycerol (40 %, v/v) at À80 8C. CVIA-modified mCherry was purified by using previously developed methods. [24] Concentrations of all proteins and enzymes were determined with the Bradford assay by using BSA standards. [26] Concentrations of Oregon Green fluorescent peptides were determined spectroscopically (e 492 = 85 000 m À1 cm À1 , 20 mm Tris, pH 9.0). [27] Oregon Green carboxylic acid was purchased from Molecular Probes. ZipTips (m-C18) were purchased from Millipore. TBTA ligand used for click reactions and diphosphate 2 were synthesized as previously described. [14, 28] MS grade trypsin was purchased from Promega. All other chemicals were purchased from Sigma-Aldrich.
(E)-2-Methyl-4-(tetrahydro-2H-pyran-2-yloxy)but-2-en-1-ol (7): First, previously described procedures were followed to protect the Figure 4 . P. aeruginosa Hcp1 is efficiently prenylated by PFTase and its solubility depends on the length of the lipid moiety. A) MALDI mass spectra of tryptic digests of unmodified Hcp1-CVIA and Hcp1-CVIA modified with either 2 (24) or 3 (22) . An asterisk in each spectrum indicates the position of the diagnostic peptide. A zoomed area surrounding this region is provided in the insets. The spectra lack great overall similarity due to the presence or absence of additional peaks contributed by PFTase tryptic peptides. In the case of Hcp1-CVIA, reactions with 3, excess PFTase was utilized; therefore, PFTase-originating peaks are particularly prominent. B) C5-Alkyne modified Hcp1 (22) displays improved solubility properties relative to C15-azide modified Hcp1. Western blot analysis of whole reaction (R) and soluble (S) fractions of Hcp1-C15-azide (C15, 24) and Hcp1-C5-alkyne (C5, 22). C) MALDI mass spectra of tryptic digests of (22) terminal hydroxyl group of 3-methyl-2-buten-1-ol (4) with a THP group to provide compound 5, which was subsequently oxidized by using tBuOOH and H 2 SeO 3 (Scheme 2). [6] The resulting alcohol 6 (0.84 g, 4.5 mmol) was dissolved in dry THF (10 mL) and placed into a sealed tube (38 mL) with a threaded plug. Next the solution was cooled to 0 8C and NaH (380 mg, 16 mmol) was slowly added to the vessel over 2 min with the observation of some vigorous bubbling, the formation of a white precipitate and a change in color to orange-brown. The tube was capped and slowly allowed to warm to room temperature. After 1 h, the tube was opened and prechilled propargyl bromide (5.5 g, 46 mmol) was added at 0 8C. The tube was resealed and heated to 55 8C for three days at which time the solution was cooled to room temperature, quenched with H 2 O (15 mL), extracted with EtOAc (2 15 mL), washed with H 2 O (2 15 mL), concentrated, dried over Na 2 SO 4 , and purified by using flash chromatography (hexanes/EtOAc 3:1, v/v) to yield alkyne 7 as a clear light-brown oil (1.0 g, 99 % yield). (E)-3-Methyl-4-(prop-2-ynyloxy)but-2-enyltrihydrogen diphosphate (3): PPh 3 (polymer-supported beads, 500 mg, 1.9 mmol) was suspended in a solution of alcohol 8 (100 mg, 0.96 mmol) dissolved in dry CH 2 Cl 2 (1.0 mL) for 30 min to allow the resin to swell. At that time CBr 4 (380 mg, 1.2 mmol) was added and the reaction was gently stirred for 20 h at which time the beads were removed by filtration and the filtrate was concentrated and purified by using flash chromatography (hexanes/EtOAc 3:1, v/v) to afford bromide 9, which was used without additional characterization or purification.
Next, bromide 9 (30 mg, 0.15 mmol) and (nBu 4 N) 3 HP 2 O 7 [14] (340 mg, 0.38 mmol) were dissolved in dry CH 3 CN (2.0 mL) and stirred at room temperature for 3 h. The reaction was then monitored for remaining starting material by using TLC (hexanes/EtOAC 3:1, v/v). No starting material was observed. A column was filled with AG 50WX8 ion-exchange resin (13 cm 1.5 cm) which was converted to its ammonium form by adding three column volumes of H 2 O/ NH 4 OH (3:1, v/v) and was equilibrated with buffer C (25 mm NH 4 HCO 3 /iPrOH 49:1, v/v) until the pH of the eluant was 7.5-8.0. The reaction mixture was then dissolved in buffer C (20 mL) and applied to the equilibrated column and the eluant was collected. Additional buffer C (20 mL) was used to further elute the product and was combined with the preceding fractions. The combined fractions were lyophilized and purified by preparative RP-HPLC (isocratic, solvent A: 25 mm NaHCO 3 ); t R = 2.8 min. Product-containing fractions were lyophilized to yield 3 (23 mg, 51 % yield). À , found 299.0064.
OrG-RTRCVIA-OH (12):
The linear peptide sequence NH 2 -RTRCVIAWang was assembled by automated Fmoc SPPS by using Wang resin on an ABI 430 peptide synthesizer. A solution containing DIPCDI (1.9 mL, 12 mmol), Oregon Green carboxylic acid (10; 5.0 mg, 12 mmol), HOBt (1.8 mg, 12 mmol), DIEA (3.12 mL, 26 mmol) and DMF (800 mL) was incubated for 10 min at room temperature and added to NH 2 -RTRCVIA-Wang (40 mg, 12 mmol) in a 10 mL solid-phase reaction vessel. The vessel was then tumbled for 14 h in the dark at which time the resin was filtered, washed with DMF (6 1 mL) and CH 2 Cl 2 (3 1 mL) to yield side-chain protected peptide 11 (Scheme 3). The resultant brilliant-orange resin was dried in vacuo for 4 h, placed in Reagent K (4 mL, TFA/H 2 O/thioanisole/ phenol/ethanedithiol 82.5:5:5:5:2.5) and tumbled in the dark for 1.5 h. The orange solution containing cleaved peptide was filtered from the resin, dissolved into Et 2 O (100 mL), precipitated at À20 8C, overnight, and centrifuged to from a pellet, which was washed with Et 2 O (2 50 mL). Prenylation of OrG-RTRCVIA with alkyne 3: An enzymatic reaction (1 mL) containing 12 (2.4 mm), Tris-HCl (50 mm), pH 7.5, DTT (5 mm), MgCl 2 (10 mm), ZnCl 2 (100 mm), 3 (44 mm), and PFTase (94 mL of 13 mm solution) was incubated in a 30 8C water bath. To ensure complete reduction of any disulfide present in the starting peptide all reagents except 3 and enzyme were incubated at room temperature for 1 h. Following addition of 3, reactions were initiated by addition of enzyme. At various times aliquots (50-100 mL) were removed and analyzed by analytical HPLC (gradient: 0-60 % B over 60 min). The reaction was deemed complete after 24 h and was purified by using the above HPLC column and method. The starting material (12) had a t R of 38.2 min and the prenylated product (13) had a t R of 44.2 min (Figure 1 Kinetic analysis of 3 by using a peptide substrate: Enzymatic PFTase prenylation rates by using 3 were determined with an HPLC-based assay. An assay solution containing Tris-HCl (60 mm), pH 7.5, MgCl 2 (12 mm), ZnCl 2 (12 mm), DTT (18 mm), and 12 (2.9 mm) was prepared and allowed to incubate at room temperature for 45 min in order to ensure complete reduction of any disulfides. In 1.5 mL centrifuge tubes, 50 mL solutions of 3 were prepared so that when they were diluted into 250 mL of assay solution the final concentration of 3 was 1.0, 2.0, 5.0, 10, 15, 30, 50 or 200 mm. After the alkyne-containing solutions were diluted into assay buffer, PFTase (30 mL, 1.38 mg mL À1 ) was added to each centrifuge tube and the reaction was incubated for 90 min at 30 8C at which time each reaction was flash frozen. Each reaction was analyzed by using an HPLC equipped with a fluorescence detector and the separation conditions specified above for prenylation of OrG-RTRCVIA. Fluorescent peaks corresponding to the starting material and product were integrated and used to calculate the concentration of prenylated product in solution. Three different samples were prepared for each concentration and the average concentration of product from the three reactions was used to calculate K M,app and V max,app for 3.
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A similar procedure was performed by using 0.1, 0.3, 0.5, 1.0, 3.0, 18, and 36 mm concentrations of FPP. For FPP, PFTase (30 mL, 0.046 mg mL
À1
) was used to initiate the reaction and the reaction was incubated for 5 min at 30 8C before being flash frozen in liquid nitrogen.
Proteolysis of prenylated peptide 13 with carboxypeptidase: A prenylation reaction (6.5 mL) containing 12 (2.4 mm), Tris-HCl (50 mm), pH 7.5, DTT (15 mm), MgCl 2 (10 mm), ZnCl 2 (100 mm), 3 (44 mm), and PFTase (94 mL of 13 mm solution) was incubated for 4.5 h at 30 8C and was determined to be greater than 60 % complete by RP-HPLC. To ensure complete reduction of any disulfide present in the starting peptide all reagents except 3 and enzyme were incubated at room temperature for 1 h and the reaction was initiated by the addition of these two reagents as noted above. The prenylation reaction was allowed to incubate for 2 h at which time CPY (50 mg) dissolved in Tris (20 mm, pH 8.0) containing EDTA (20 mm, 1.0 mL) was added to the reaction. The reaction was removed from the 30 8C water bath and placed at room temperature for 2 h at which time the proteolyzed product (14) was purified by preparative RP-HPLC (gradient: 0-60 % B over 60 min). The product-containing fractions were concentrated to remove CH 3 CN and repurified by using analytical HPLC (gradient: 0-60 % B over 60 min) to obtain a product of greater than 98 % purity, t R = 40.2 min (Figure 1 . In order to reduce any disulfide linkages, all reagents except 3 and enzyme were premixed and incubated together for 1 h at room temperature. Following addition of 3 and PFTase the reaction was incubated at 30 8C for 4 h. At this time the reaction was concentrated to 500 mL by using a Centricon Ultra YM-10 filtration device and purified from excess alkyne 3 by using a NAP-5 column. The concentration of the prenylated product (16) was determined spectroscopically (e 492 = 72 000 m À1 cm
). [29] Carboxypeptidase Y proteolysis of alkyne-modified mCherry: Carboxypeptidase Y (75 mg) dissolved in 20 mL Tris-HCl (20 mm), pH 7.5, was added to prenylated protein 16 (90 mL, 165 mm) followed by the addition of Tris-HCl buffer (20 mm), pH 8.0, that was supplemented with EDTA (20 mm; 60 mL). The reaction was incubated at room temperature for 3 h, followed by incubation at 4 8C, overnight, to yield truncated mCherry protein 17 (Scheme 4). The next day the reaction was concentrated to approximately 60 mL by using a Microcon YM-10 centrifugal device and quantified by a Bradford assay by using BSA standards. [26] Immobilization of alkyne-modified mCherry to azide functionalized agarose: Two samples containing azide-modified agarose (18; 100 mL) were washed three times with NaH 2 PO 4 (50 mm), pH 7.3. One of the samples was suspended in NaH 2 PO 4 (50 mm), pH 7.3, containing alkyne-modified mCherry (80 mm; 16), TBTA ligand (100 mm), CuSO 4 (1 mm), and TCEP (1 mm; 60 mL). The other sample was suspended in the same mixture but without CuSO 4 . The samples were treated for 4 h at room temperature at which time the supernatant was collected and the beads were washed with NaH 2 PO 4 (50 mm) that contained NaCl (1 m; 3 100 mL). The copper deficient sample contained beads that looked the same before the reaction (white in color); however, the reaction that included copper contained beads that were visibly red without the use of UV light. Under fluorescent light from an inverted microscope fitted with a Cy5 filter, the beads that were treated with copper were bright red while the copper deficient control showed no fluorescence (Figure 2 , compare panels A and B).
Control reactions done in the absence of TBTA and TCEP did not indicate conjugation of alkyne-modified mCherry (16) to azide functionalized beads (data not shown). Control reactions performed by using unmodified mCherry protein 15 were also unreactive (Figure 2, panel C) . The same procedure was used with prenylated mCherry protein that was treated with CPY (17) and yielded identical results (compare Figure 2 A to 3 A) .
Hcp1-CVIA cloning, over-expression, and purification: The CVIAtag was appended to the C terminus of Hcp1 pET29B hcp1 [25] by standard cloning procedures with PCR forward primer 5'-GGA GAT ATA CAT ATG GCT GTT GAT ATG TTC ATC AAG-3' and reverse primer 5'-GGA TCC TCA GGC GAT CAC GCA GTG GTG GTG GTG GTG GTG CTC G-3'. This places the amino acid sequence CVIA Cterminal to the His 6 -tag. Hcp1-CVIA was expressed and purified as described previously. [25] Prenylation and CPY proteolysis of Hcp1 with 3: An enzymatic reaction (0.3 mL) was prepared that contained Tris-HCl (50 mm), pH 7.5, MgCl 2 (10 mm), ZnCl 2 (10 mm), DTT (15 mm), Hcp1 (2.4 mm; 21), 3 (57 mm), and PFTase (50 mL, 1 mg mL À1 stock solution). In order to reduce any disulfide linkages, all reagents except 3 and enzyme were premixed and incubated together for 1 h at room temperature. Following addition of 3 and PFTase, the reaction was incubated at 30 8C for 3 h, at which time an aliquot was removed for analysis by mass spectrometry. MALDI-MS for C-terminal fragment QNVQALEHHHHHHC[C 8 For CPY-treated samples, a prenylation reaction was performed as described above (Scheme 5). After 2 h, 40 mL CPY (100 mg) dissolved in Tris (20 mm), pH 7.5, was added to the reaction and incubated at room temperature without being stirred. Prenylation of Hcp1 with 2: An enzymatic reaction (3.1 mL) was prepared that contained Tris-HCl (50 mm), pH 7.5, MgCl 2 (10 mm), ZnCl 2 (10 mm), DTT (15 mm), Hcp1 (2.4 mm; 21), 2 (20 mm), and PFTase (50 mL, 1 mg mL À1 stock solution). Thiol reduction was preformed as described for the prenylation of Hcp1 with 3. Following addition of 2 and enzyme, the reaction was incubated at 30 8C for 3 h and subsequently analyzed by mass spectrometry. 
(Figure 4 A).
Tryptic digest of prenylated Hcp1-CVIA and prenylated Hcp1-CVIA treated with carboxypeptidase: Prenylated (22) and unprenylated (21) Hcp1-CVIA were digested in PFTase reaction buffer by using MS grade trypsin at 1:20 (w/w trypsin to Hcp1) for 18 h at room temperature. The reaction was stopped with acetic acid (5 %) and peptides were purified according to the manufacturer's protocol by using m-C18 ZipTips.
Mass spectrometry of tryptic peptides: Peptide samples (0.4 mL) were spotted onto a target plate along with 0.6 mL matrix solution (a-cyano-hydroxycinnamic acid in 0.1 % TFA, 70 % CH 3 CN) and allowed to air-dry. Analysis was accomplished on a 4800 MALDI-TOF/ Scheme 4. Prenylation, "VIA" proteolysis, and immobilization of mCherry-CVIA by using 3, CPY, and azide-modified agarose.
Scheme 5. Prenylation of Hcp1 with prenyl alkyne 3 and prenyl azide 2. Hcp1 prenylated with alkyne 3 b was subsequently proteolyzed by using CPY.
TOF mass analyzer operating in the positive mode. Each MS spectrum is the accumulated spectra of 1000 laser shots (Nd:YAG (355 nm), 200 Hz) consisting of 50 shots per subspectrum and 20 subspectra over a mass range of 800-4000 Da. The first five shots were discarded and the accelerating voltage was operated at 20 kV. To each spot, 20 fmol of Glu-fibrinopeptide D were added to serve as an internal calibration mass.
Prenylated Hcp1-CVIA solubility assay: To determine the relative solubility of Hcp1-CVIA conjugated to either 2 or 3, an aliquot of the final reaction mixture was removed and subjected to centrifugation at 16 000 g at 4 8C for 30 min. Equal volumes of the supernatant of this sample and untreated, homogenized reaction mixture were analyzed for the presence of Hcp1 by using Western blotting procedures described previously (Figure 4 B) . [30] 
